Am J Psychiatry 157:975-981, June 2000
© 2000 American Psychiatric Association
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study
David C. Henderson, M.D.,
Enrico Cagliero, M.D.,
Colin Gray,
Rima A. Nasrallah, B.S.,
Doug L. Hayden, M.A.,
David A. Schoenfeld, Ph.D., and
Donald C. Goff, M.D.
ABSTRACT
OBJECTIVE: The goal of this 5-year naturalistic study of patients treated with clozapine was to examine the incidence of treatment-emergent diabetes mellitus in relation to other factors, including weight gain, lipid abnormalities, age, clozapine dose, and treatment with valproate.METHOD: Data on age, gender, race, diagnosis, family history of diabetes, and age at clozapine initiation were collected from medical records of 82 outpatients with schizophrenia or schizoaffective disorder. Clozapine dose, data on use of valproate, and laboratory test results were recorded at 6-month intervals.RESULTS: The mean age at the time of clozapine initiation of the 82 patients was 36.4 years; 26.8% of the patients were women, and 91.5% were Caucasian. The mean baseline weight was 175.5 lb, and the mean body mass index was 26.9 kg/m2. Thirty patients (36.6%) were diagnosed with diabetes during the 5-year follow-up. Weight gain, use of valproate, and total daily dose of clozapine were not significant risk factors for developing diabetes mellitus. Patients experienced significant weight gain that continued until approximately month 46 from initiation of clozapine. There was a nonsignificant increase in total serum cholesterol and a significant increase in serum triglycerides level.CONCLUSIONS: The results support the hypotheses that patients treated with clozapine experience significant weight gain and lipid abnormalities and appear to be at increased risk for developing diabetes.
This article has been cited by other articles:
|
|
|
|
 
M. Fell, J. Neill, N. Anjum, L. Peltola, and K. Marshall
Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats
J Psychopharmacol,
March 1, 2008;
22(2):
182 - 186.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. F. Buckley, A. Foster, and B. Miller
Schizophrenia Host Vulnerability and Risk of Metabolic Disturbances During Treatment with Antipsychotics
Focus,
January 1, 2008;
6(2):
172 - 179.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. VIRMANI, Z. K. BINIENDA, S. F. ALI, and F. GAETANI
Metabolic Syndrome in Drug Abuse
Ann. N.Y. Acad. Sci.,
December 1, 2007;
1122(1):
50 - 68.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.H. Barnett, P. Mackin, I. Chaudhry, A. Farooqi, R. Gadsby, A. Heald, J. Hill, H. Millar, R. Peveler, A. Rees, et al.
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
J Psychopharmacol,
June 1, 2007;
21(4):
357 - 373.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. M. Noel
ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders
Am. J. Health Syst. Pharm.,
April 15, 2007;
64(8):
863 - 876.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Olfson, S. C. Marcus, P. Corey-Lisle, A.V. Tuomari, P. Hines, and G. J. L'Italien
Hyperlipidemia Following Treatment With Antipsychotic Medications
Am J Psychiatry,
October 1, 2006;
163(10):
1821 - 1825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. L. Lambert, F. E. Cunningham, D. R. Miller, G. W. Dalack, and K. Hur
Diabetes Risk Associated with Use of Olanzapine, Quetiapine, and Risperidone in Veterans Health Administration Patients with Schizophrenia
Am. J. Epidemiol.,
October 1, 2006;
164(7):
672 - 681.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. VIRMANI, Z. BINIENDA, S. ALI, and F. GAETANI
Links between Nutrition, Drug Abuse, and the Metabolic Syndrome.
Ann. N.Y. Acad. Sci.,
August 1, 2006;
1074:
303 - 314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. M. Bai, C.-C. Lin, J.-Y. Chen, C.-Y. Lin, T.-P. Su, and P. Chou
Association of Initial Antipsychotic Response to Clozapine and Long-Term Weight Gain
Am J Psychiatry,
July 1, 2006;
163(7):
1276 - 1279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Best, A. P. Yates, and G. P. Reynolds
Actions of antipsychotic drugs on pancreatic {beta}-cell function: contrasting effects of clozapine and haloperidol
J Psychopharmacol,
November 1, 2005;
19(6):
597 - 601.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Haddad
Weight change with atypical antipsychotics in the treatment of schizophrenia
J Psychopharmacol,
November 1, 2005;
19(6_suppl):
16 - 27.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. McDevitt, J. Wilbur, J. Kogan, and J. Briller
A Walking Program for Outpatients in Psychiatric Rehabilitation: Pilot Study
Biol Res Nurs,
October 1, 2005;
7(2):
87 - 97.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. L. Leslie and R. A. Rosenheck
Pharmacotherapy and Health Care Costs Among Patients With Schizophrenia and Newly Diagnosed Diabetes
Psychiatr Serv,
July 1, 2005;
56(7):
803 - 809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ader, S. P. Kim, K. J. Catalano, V. Ionut, K. Hucking, J. M. Richey, M. Kabir, and R. N. Bergman
Metabolic Dysregulation With Atypical Antipsychotics Occurs in the Absence of Underlying Disease A Placebo-Controlled Study of Olanzapine and Risperidone in Dogs
Diabetes,
March 1, 2005;
54(3):
862 - 871.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Connolly and C. Kelly
Lifestyle and physical health in schizophrenia
Advan. Psychiatr. Treat.,
March 1, 2005;
11(2):
125 - 132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Henderson, E. Cagliero, P. M. Copeland, C. P. Borba, E. Evins, D. Hayden, M. T. Weber, E. J. Anderson, D. B. Allison, T. B. Daley, et al.
Glucose Metabolism in Patients With Schizophrenia Treated With Atypical Antipsychotic Agents: A Frequently Sampled Intravenous Glucose Tolerance Test and Minimal Model Analysis
Arch Gen Psychiatry,
January 1, 2005;
62(1):
19 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Schur, L. Sikich, R. L. Findling, R. P. Malone, M. L. Crismon, A. Derivan, J. C. MacIntyre II, E. Pappadopulos, L. Greenhill, N. Schooler, et al.
Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY), Part I: A Review
Focus,
October 1, 2004;
2(4):
596 - 607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Leslie and R. A. Rosenheck
Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications
Am J Psychiatry,
September 1, 2004;
161(9):
1709 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Marder, S. M. Essock, A. L. Miller, R. W. Buchanan, D. E. Casey, J. M. Davis, J. M. Kane, J. A. Lieberman, N. R. Schooler, N. Covell, et al.
Physical Health Monitoring of Patients With Schizophrenia
Am J Psychiatry,
August 1, 2004;
161(8):
1334 - 1349.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Cavazzoni, N. Mukhopadhyay, C. Carlson, A. Breier, and J. Buse
Retrospective analysis of risk factors in patients with treatment-emergent diabetes during clinical trials of antipsychotic medications
The British Journal of Psychiatry,
April 1, 2004;
184(47):
s94 - s101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. D. Howes, A. Bhatnagar, F. P. Gaughran, S. A. Amiel, R. M. Murray, and L. S. Pilowsky
A Prospective Study of Impairment in Glucose Control Caused by Clozapine Without Changes in Insulin Resistance
Am J Psychiatry,
February 1, 2004;
161(2):
361 - 363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I A MacFarlane, G V Gill, D Finnegan, and J Pinkney
Diabetes in a high secure hospital
Postgrad. Med. J.,
January 1, 2004;
80(939):
35 - 37.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. WEHRING, D. L. KELLY, R. C. LOVE, and R. R. CONLEY
Deaths From Diabetic Ketoacidosis After Long-Term Clozapine Treatment
Am J Psychiatry,
December 1, 2003;
160(12):
2241 - 2242.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Lafayette, W. F. Pirl, and D. C. Henderson
Low-Dose Clozapine and Diabetic Ketoacidosis
Psychosomatics,
June 1, 2003;
44(3):
249 - 252.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. B. Sneed and E. C. Gonzalez
Type 2 Diabetes Mellitus Induced by an Atypical Antipsychotic Medication
J Am Board Fam Med,
May 1, 2003;
16(3):
251 - 254.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E.J. Lean and F.-G. Pajonk
Patients on Atypical Antipsychotic Drugs: Another high-risk group for type 2 diabetes
Diabetes Care,
May 1, 2003;
26(5):
1597 - 1605.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Freudenreich and T. A. Stern
Clinical Experience With the Management of Schizophrenia in the General Hospital
Psychosomatics,
February 1, 2003;
44(1):
12 - 23.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Lindenmayer, P. Czobor, J. Volavka, L. Citrome, B. Sheitman, J. P. McEvoy, T. B. Cooper, M. Chakos, and J. A. Lieberman
Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics
Am J Psychiatry,
February 1, 2003;
160(2):
290 - 296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Koro, D. O. Fedder, G. J. L'Italien, S. Weiss, L. S. Magder, J. Kreyenbuhl, D. Revicki, and R. W. Buchanan
An Assessment of the Independent Effects of Olanzapine and Risperidone Exposure on the Risk of Hyperlipidemia in Schizophrenic Patients
Arch Gen Psychiatry,
November 1, 2002;
59(11):
1021 - 1026.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Doraiswamy
Understanding Risks
Psychiatr News,
November 1, 2002;
37(21):
30 - 30.
[Full Text]
|
|
|
|
|
|
|
V. S. Basile, M. Masellis, S. G. Potkin, and J. L. Kennedy
Pharmacogenomics in schizophrenia: the quest for individualized therapy
Hum. Mol. Genet.,
October 1, 2002;
11(20):
2517 - 2530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Desai, R. A. Rosenheck, B. G. Druss, and J. B. Perlin
Mental Disorders and Quality of Diabetes Care in the Veterans Health Administration
Am J Psychiatry,
September 1, 2002;
159(9):
1584 - 1590.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Goff
A 23-Year-Old Man With Schizophrenia
JAMA,
June 26, 2002;
287(24):
3249 - 3257.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Peet
Essential fatty acids: theoretical aspects and treatment implications for schizophrenia and depression
Advan. Psychiatr. Treat.,
May 1, 2002;
8(3):
223 - 229.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Sernyak, D. L. Leslie, R. D. Alarcon, M. F. Losonczy, and R. Rosenheck
Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of Schizophrenia
Am J Psychiatry,
April 1, 2002;
159(4):
561 - 566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Newcomer, D. W. Haupt, R. Fucetola, A. K. Melson, J. A. Schweiger, B. P. Cooper, and G. Selke
Abnormalities in Glucose Regulation During Antipsychotic Treatment of Schizophrenia
Arch Gen Psychiatry,
April 1, 2002;
59(4):
337 - 345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Schneider and J. L. Levenson
Update in Psychiatry
Ann Intern Med,
February 19, 2002;
136(4):
293 - 301.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Melkersson and A.-L. Hulting
Recovery From New-Onset Diabetes in a Schizophrenic Man After Withdrawal of Olanzapine
Psychosomatics,
February 1, 2002;
43(1):
67 - 70.
[Full Text]
|
|
|
|
|
|
|
G. Koren, T. Cohn, D. Chitayat, B. Kapur, G. Remington, D. M. Reid, and R. B. Zipursky
Use of Atypical Antipsychotics During Pregnancy and the Risk of Neural Tube Defects in Infants
Am J Psychiatry,
January 1, 2002;
159(1):
136 - 137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. C. Lund, P. J. Perry, J. M. Brooks, and S. Arndt
Clozapine Use in Patients With Schizophrenia and the Risk of Diabetes, Hyperlipidemia, and Hypertension: A Claims-Based Approach
Arch Gen Psychiatry,
December 1, 2001;
58(12):
1172 - 1176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Glassman and J. T. Bigger Jr.
Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death
Am J Psychiatry,
November 1, 2001;
158(11):
1774 - 1782.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Luna and M. N. Feinglos
Drug-Induced Hyperglycemia
JAMA,
October 24, 2001;
286(16):
1945 - 1948.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sauer, N. Funnell, and A. Reveley
Hyperglycaemia and myoclonus with clozapine
Psychiatr. Bull.,
September 1, 2001;
25(9):
360 - 361.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Procyshyn, N. B. Kennedy, S. Marriage, and K. M. Wasan
Plasma Protein and Lipoprotein Distribution of Clozapine
Am J Psychiatry,
June 1, 2001;
158(6):
949 - 951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kapur and G. Remington
Atypical antipsychotics
BMJ,
December 2, 2000;
321(7273):
1360 - 1361.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2000
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
